How Methylation Affects Drug Response in Colon Cancer
Author Information
Author(s): Habano Wataru, Gamo Toshie, Terashima Jun, Sugai Tamotsu, Otsuka Koki, Wakabayashi Go, Ozawa Shogo
Primary Institution: Iwate Medical University
Hypothesis
Are epigenetic mechanisms involved in the regulation of PXR/CYP3A4 pathways in colon cancer cells?
Conclusion
PXR promoter methylation regulates intestinal PXR and CYP3A4 expression and may influence drug responses in colon cancer cells.
Supporting Evidence
- The study classified colon cancer cell lines into high and low expression groups based on PXR/CYP3A4 mRNA levels.
- DNA methylation of the PXR promoter was more prevalent in low expression cells compared to high expression cells.
- Treatment with a demethylating agent increased PXR and CYP3A4 mRNA levels in low expression cells.
Takeaway
The study found that changes in DNA methylation can affect how colon cancer cells respond to drugs by altering the levels of important proteins.
Methodology
The study used quantitative real-time PCR and bisulfite sequencing on colon cancer cell lines and tissue samples to evaluate mRNA levels and DNA methylation status.
Limitations
The study was limited to a small number of cell lines and tissue samples, which may not represent all colon cancer cases.
Participant Demographics
The study involved 18 patients with colorectal cancers who did not receive chemotherapy before surgery.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website